Author

Edwin J. Weeber

University of South FloridaORCID 0009-0004-5213-2109Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:non-human primate· 1 Organism:plant (other)· 1

Frequent Co-Authors

Annalise SchlaferiD· 2 shared Anne E. AndersoniD· 2 shared David Jay SegaliD· 2 shared Jill L. SilvermaniD· 2 shared Kevin R. NashiD· 2 shared Kranti Konganti· 2 shared Luke S. MyersiD· 2 shared Sarah ChristianiD· 2 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetics

Annalise SchlaferORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A preclinical pig model of Angelman syndrome mirrors the early developmental trajectory of the human condition

Luke S. Myers, Sarah Christian, Sean G. Simpson, Renan B. Sper, Clint Taylor, Laura Montes, Thomas Jepp, Daniela Ramos, Livia Schuller, Kranti Konganti, Wade O. Friedeck, Ozair Habib, McKaela Hodge, Alasdair J. Taylor, Ashley Coffell, , Scott V. Dindot

This paper describes a pig model of Angelman syndrome that mirrors early developmental symptoms observed in humans.

Proceedings of the National Academy of Sciences · Jul 21, 2025Peer-reviewedGenetics

Development of an ASO therapy for Angelman syndrome by targeting an evolutionarily conserved region at the start of the UBE3A-AS transcript

Scott V. Dindot, Sarah Christian, William J. Murphy, Allyson Berent, Jennifer Panagoulias, Annalise Schlafer, Johnathan L. Ballard, Kamelia Radeva, Ruth Robinson, Luke S. Myers, Thomas Jepp, Hillary Shaheen, Paul Hillman, Kranti Konganti, Andrew Hillhouse, , Jill L. Silverman

This paper describes the development of an antisense oligonucleotide (ASO) therapy targeting the UBE3A-AS transcript to reactivate paternal UBE3A expression in Angelman syndrome models.

Science Translational Medicine · Mar 22, 2023Peer-reviewedGenetics